Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01174823 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients
A Phase 2 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 245
- Enrollment target
NCT01174823: Completed Phase 2 study, sponsored by Bausch & Lomb Incorporated.
NCT01174823 is a Phase 2 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 245 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (84% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01174823, a Phase 2 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 245 participants
- Enrollment target
Study Summary
The purpose of this study is to study the safety and efficacy of bepotastine besilate ophthalmic solution in allergic conjunctivitis patients.
Primary Outcome
Responses to questions relating to symptoms and daily activities in the RQLQ were provided for 28 questions encompassing the 7 major domains of activities, sleep, non-nose/eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotional state. Each response to an RQLQ question was provided on a scale of 0-6 units, where 0 = not troubled/none of the time and 6 = extremely troubled/all of the time. The minimum total score was 0 units and the maximum total score was 42 units, with high
Interventions
- DRUG bepotastine besilate ophthalmic solution
- DRUG placebo comparator ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2010-06 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
What the finished NCT01174823 record still lists
NCT01174823 is an interventional study that assigns participants to a tested intervention. The registered 245 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (84% higher).
The record links to 0 conditions, and to 2 interventions - of which bepotastine besilate ophthalmic solution is the first listed.
NCT01174823 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01174823 about?
NCT01174823 is a clinical study titled "Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients". The purpose of this study is to study the safety and efficacy of bepotastine besilate ophthalmic solution in allergic conjunctivitis patients.
What is the current status of trial NCT01174823?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 245 participants. The study started on 2010-06. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01174823?
The interventions under investigation include: bepotastine besilate ophthalmic solution (DRUG), placebo comparator ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT01174823?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01174823's enrollment target sits among peer trials
245 234th of 2000 higher than 1,766 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03645928 · 245 participants · Phase 2
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
- NCT04718168 · 245 participants · NA
GORE® ENFORM Biomaterial Product Study
- NCT05145127 · 245 participants · Phase 3
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- NCT05446259 · 245 participants
Degenerative Cervical Myelopathy Repository
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia